Senti Biosciences Holdings Inc

sentibio.com

What Do They Do?

Develops genetically programmed cell and gene therapies for patients with cancer and other incurable diseases, including therapies made from donor immune cells.

How Do They Make Money?

The company earns collaboration revenue under its BlueRock agreement from an option-extension fee, spread over the extension period.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $61.4M in FY2025.

Operating income, FY2025

−312632% of revenue

▲ +13% (Loss) vs FY2024 (−$61M)

Net income, FY2025

−279091% of revenue

▲ +16% (Loss) vs FY2024 (−$52.8M)

Free cash flow, FY2025

−198364% of revenue

▲ +5% (Loss) vs FY2024 (−$41.4M)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: vs $0 in Q2 FY2025
Net income: ▼ −13% (Loss); vs −$14.7M in Q2 FY2025

Jul 15, 2026 Agreed to merge most of its business into a Celadon affiliate The public company would retain intellectual property, collaborations and early programs focused on Regulator Dial; stockholder approval remains pending.

Shrinking. Revenue fell 99% in 4 years, from $2.8M in FY2021 to $22K in FY2025, about 70% a year.

Who Do They Compete With?

Competes with A2 Biotherapeutics, Arsenal Biosciences, Beam Therapeutics, CRISPR Therapeutics, Encoded Therapeutics, ImmPACT Bio USA, Intellia Therapeutics, MeiraGTx Holdings, Obsidian Therapeutics, Strand Therapeutics, Allogene Therapeutics, Artiva Biotherapeutics, Atara Biotherapeutics, Bristol-Myers Squibb, Century Therapeutics, Caribou Biosciences, Cytovia Therapeutics, Fate Therapeutics, Gilead Sciences, and Lyell Immunopharma

Comments